ClinicalTrials.gg
RecruitingNCT05020236MAGNETISMM-5Updated Aug 24, 2026

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

A Phase 3 interventional study of Elranatamab and Daratumumab in Multiple Myeloma, sponsored by Pfizer. Recruiting at 237 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
893
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Planned enrollment
2nd of 31
893 · median 75
Started
2021
with 5 others
Phase 3
5 of 31
4 open now
Primary completion
2026-02
later than 1 of 24 live
Registered
5th of 31
by date
Lead sponsor
13 of 31
Pfizer

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2021, is one of 5 in phase 3, reaches primary completion later than 1 of the 24 other live ones, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study.

Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab.

People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab.

Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab.

All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Elranatamab
  • PF-06863135
  • B-Cell Maturation Antigen
  • BCMA
  • Bispecific antibody
  • BCMA-CD3 bispecific antibody
  • Daratumumab
  • Pomalidomide
  • Multiple myeloma
  • Relapsed multiple myeloma
  • Refractory multiple myeloma
  • MagnetisMM-5
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al, 2014).
  • based on IMWG criteria as defined by at least 1 of the following:

    • Serum M-protein ≥0.5 g/dL.
    • Urinary M-protein excretion ≥200 mg/24 hours.
    • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or >1.65).
  • Prior anti-multiple myeloma therapy including treatment with lenalidomide.
  • performance status ≤2.
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤1.
  • Not pregnant and willing to use .

Exclusion criteria

Exclusion Criteria:

  • Smoldering multiple myeloma.
  • Plasma cell leukemia.
  • Amyloidosis.
  • POEMS Syndrome.
  • Stem cell transplant within 12 weeks prior to enrolment, or active .
  • Active , , SARS-CoV2, , or any active, uncontrolled bacterial, fungal, or viral infection.
  • Any other active within 3 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Previous treatment with a BCMA-directed therapy.
  • within 4 weeks of the first dose of study intervention.
  • Administration with an product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
893 participants (estimated)

Study arms

  • Experimental
    Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab

    Drug: Elranatamab · Drug: Daratumumab

  • Experimental
    Part 2 Randomized Arm A: Elranatamab

    Drug: Elranatamab

  • Experimental
    Part 2 Randomized Arm B: Elranatamab + Daratumumab

    Drug: Elranatamab · Drug: Daratumumab

  • Active comparator
    Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone

    Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Part 3 Arm D: Elranatamab

    Drug: Elranatamab

  • Experimental
    Part 3 Arm E: Elranatamab + Daratumumab

    Drug: Elranatamab · Drug: Daratumumab

Interventions

  • subcutaneous

    Also known as: PF-06863135

  • Daratumumab / hyaluronidase, subcutaneous

    Also known as: Darzalex Faspro; Darzalex solution for injection

  • oral

    Also known as: Pomalyst, Imnovid

  • oral

06

What researchers measure

Primary outcomes

  1. Part 1 Safety Lead-In: Incidence of dose limiting toxicities

    Time frame: First 42 days after first elranatamab dose

  2. Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months

  3. Part 3: Frequency of treatment-emergent adverse events

    Time frame: First 84 days after first elranatamab dose

Secondary outcomes

  1. Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months

  2. Overall survival

    Time frame: From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months

  3. Objective response rate per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months

  4. Duration of response per International Myeloma Working Group criteria

    Time frame: From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months

  5. Time to response per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of confirmed objective response, assessed up to 51 months

  6. Complete response rate per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months

  7. Duration of complete response per International Myeloma Working Group criteria

    Time frame: From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 51 months

  8. Minimal residual disease negativity rate per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months

  9. Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 51 months

  10. Progression free survival on next-line treatment per International Myeloma Working Group criteria

    Time frame: From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months

  11. Frequency of treatment-emergent adverse events

    Time frame: From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy.

  12. Frequency of abnormal laboratory results

    Time frame: From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy.

  13. Rate of Grade ≥2 cytokine release syndrome

    Time frame: First 28 days after first elranatamab dose

  14. Elranatamab pharmacokinetics by pre- and post-dose concentrations

    Time frame: From date of first dose through up to 14 days after date of last dose of elranatamab

  15. Elranatamab immunogenicity by anti-drug antibodies against elranatamab

    Time frame: From date of first dose through up to 14 days after date of last dose of elranatamab

  16. Daratumumab pharmacokinetics by pre-dose concentrations

    Time frame: From date of first dose through up to 14 days after date of last dose of daratumumab

  17. Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30

    Time frame: From date of informed consent through up to 35 days after date of last dose of study intervention

  18. Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20

    Time frame: From date of informed consent through up to 35 days after date of last dose of study intervention

07

Study locations

80 of 237 sites recruiting
  • Clovis Community Medical Center
    Clovis, California 93611, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Community Cancer Institute
    Clovis, California 93611, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of California San Francisco
    Fresno, California 93701, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Community Regional Medical Center
    Fresno, California 93721, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UCHealth Poudre Valley Hospital
    Fort Collins, Colorado 80524, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UCHealth Harmony
    Fort Collins, Colorado 80528, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UCHealth Greeley Hospital
    Greeley, Colorado 80634, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UCHealth - Medical Center of the Rockies
    Loveland, Colorado 80538, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sylvester Comprehensive Cancer Center - Aventura
    Aventura, Florida 33180, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
    Coral Gables, Florida 33146, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center - Coral Springs
    Coral Springs, Florida 33065, United States
    Recruiting
  • University of Miami Hospital and Clinics - Deerfield Beach
    Deerfield Beach, Florida 33442, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center - Hollywood
    Hollywood, Florida 33021, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
    Recruiting
  • University of Miami Hospital and Clinics
    Miami, Florida 33136, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center - Kendall
    Miami, Florida 33176, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center - Plantation
    Plantation, Florida 33324, United States
    Recruiting
  • East Jefferson General Hospital
    Metairie, Louisiana 70006, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MSK Basking Ridge
    Basking Ridge, New Jersey 07920, United States
    Recruiting
  • MSK Monmouth
    Middletown, New Jersey 07748, United States
    Recruiting
  • MSK Bergen
    Montvale, New Jersey 07645, United States
    Recruiting
  • MSK Commack
    Commack, New York 11725, United States
    Recruiting
  • MSK Westchester
    Harrison, New York 10604, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
    New York, New York 10021, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center - Main Campus
    New York, New York 10065, United States
    Recruiting
  • MSK Nassau
    Uniondale, New York 11553, United States
    Recruiting
  • Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming)
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1426, Argentina
    Terminated

    Not enrolling at this site — choose another above.

  • FUNDALEU - Fundacion para combatir la Leucemia
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1114AAN, Argentina
    Recruiting
  • FUNDALEU -Fundación para combatir la leucemia
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1114AAP, Argentina
    Recruiting
  • FUNDALEU
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1114AAP, Argentina
    Recruiting
  • Hospital Italiano de La Plata
    La Plata, Buenos Aires B1900XI, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Austral
    Presidente Derqui, Buenos Aires B1629AHJ, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sanatorio de La Mujer
    Rosario, Santa Fe Province S2000ORE, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
    Recruiting
  • QScan Radiology Clinics
    Clayfield, Queensland 4011, Australia
    Recruiting
  • Gallipoli Medical Research Foundation
    Greenslopes, Queensland 4120, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Greenslopes Private Hospital
    Greenslopes, Queensland 4120, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
    Recruiting
  • Epworth Freemasons
    East Melbourne, Victoria 3002, Australia
    Recruiting
  • St Vincent's Hospital (Melbourne)
    Fitzroy, Victoria 3065, Australia
    Recruiting
  • Barwon Health
    Geelong, Victoria 3220, Australia
    Recruiting
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Epworth Healthcare
    Richmond, Victoria 3121, Australia
    Recruiting
  • Slade Pharmacy
    Richmond, Victoria 3121, Australia
    Recruiting
  • Linear Clinical Research
    Perth, Western Australia 6009, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Krems
    Krems, Lower Austria 3500, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Klinik Ottakring
    Vienna, State of Vienna 1160, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinik für Innere Medizin V Innsbruck
    Innsbruck, 6020, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Uniklinikum Salzburg
    Salzburg, 5020, Austria
    Recruiting
  • Medizinische Universität Wien
    Vienna, 1090, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Grand Hôpital de Charleroi
    Gilly, Hainaut 6060, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU UCL Namur (site Godinne)
    Yvoir, Namur 5530, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador
    Salvador, Estado de Bahia 41253-190, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro de Pesquisa Clínica - Área Administrativa
    Porto Alegre, Rio Grande do Sul 90850-170, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Mae de Deus
    Porto Alegre, Rio Grande do Sul 90880-480, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • BP - A Beneficencia Portuguesa de São Paulo
    São Paulo, São Paulo 01321-001, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clínica Médica São Germano LTDA
    SP, São Paulo 04537-080, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Américas Medical City
    Rio de Janeiro, 22775001, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto de Educação, Pesquisa e Gestão em Saúde
    Rio de Janeiro, 22793-080, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis
    São Paulo, 01232-010, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IDOR Ensino e Pesquisa
    São Paulo, 01401-002., Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HU UNIFESP / SPDM - Hospital São Paulo
    São Paulo, 04024-002, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universidade Federal de Sao Paulo
    São Paulo, 04024-002, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clínica Médica São Germano S/S Ltda
    São Paulo, 04537-080, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto D'Or de Pesquisa e Ensino (IDOR)
    São Paulo, 04543-000, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto D'Or de Pesquisa e Ensino (IDOR)
    São Paulo, 04544-000, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • QEII Health Sciences Centre - Victoria General Site
    Halifax, Nova Scotia B3H 2Y9, Canada
    Recruiting
  • Hamilton Health Sciences-Juravinski Cancer Centre
    Hamilton, Ontario L8V5C2, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CIUSSS de l'Est-de-l'Île-de-Montréal
    Montreal, Quebec H1T2M4, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Saskatoon Cancer Center
    Saskatoon, Saskatchewan S7N4H4, Canada
    Recruiting
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Recruiting
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
    Recruiting
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
    Recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510555, China
    Recruiting
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518035, China
    Recruiting
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
  • Nanjing Drum Tower Hospital , The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
    Recruiting
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221006, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jilin Province Cancer Hospital
    Changchun, Jilin 130000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Recruiting
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jinan Central Hospital
    Jinan, Shandong 250100, China
    Recruiting
  • Institute of hematology&blood disease hospital
    Tianjin, Tianjin Municipality 301636, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Recruiting
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
  • Beijing Boren Hospital
    Beijing, 100070, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, 100730, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chongqing University Cancer Hospital
    Chongqing, 400030, China
    Recruiting
  • Fakultní nemocnice Brno Bohunice
    Brno, Brno-m?sto 625 00, Czechia
    Recruiting
  • Fakultni Nemocnice Plzen
    Plzen - Lochotin, Plzeň Region 304 60, Czechia
    Recruiting
  • Fakultni poliklinika
    Prague, Praha 2 120 00, Czechia
    Recruiting

Showing the first 100 of 237 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Feb 2026, 52 months.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 52 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2021
First posted
Aug 25, 2021
StartActual
Oct 4, 2021
Primary completionActual
Feb 26, 2026
CompletionEst.
May 31, 2027
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05020236
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 25, 2021
Start date
Oct 4, 2021
Primary completion
Feb 26, 2026
Completion
May 31, 2027 (estimated)
Last update
Aug 24, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elranatamab · Daratumumab

Start the discussion